{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-071659","form_type":"8-K","ticker":"RFL","cik":"0001713863","company_name":"Rafael Holdings, Inc.","filed_at":"2024-08-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.230752+00:00","generated_at":"2026-05-31T08:05:52.474650+00:00","sec_items":["1.01","2.03","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rafael Holdings to merge with Cyclo Therapeutics; deal values Cyclo at $0.95/share","bullets":["Rafael issues Class B common stock to Cyclo holders based on exchange ratio valuing Cyclo at $0.95/share and Rafael at net cash value.","Merger expected to close in Q4 2024, subject to shareholder approvals and SEC effectiveness of Form S-4.","Rafael will fund Cyclo's TransportNPC Phase 3 trial to 48-week interim analysis; enrollment complete, results expected mid-2025.","Cyclo directors enter 6-month lock-up; Howard Jonas agrees to vote in favor of share issuance.","Rafael also provides $3M convertible note to Cyclo under amended note purchase agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-071659","json":"https://secwatch.observer/filing/0001213900-24-071659.json","markdown":"https://secwatch.observer/filing/0001213900-24-071659.md","text":"https://secwatch.observer/filing/0001213900-24-071659.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1713863/000121390024071659/0001213900-24-071659-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1713863/000121390024071659/ea0212085-8k425_rafael.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:05:52.474650+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}